Introduction {#Sec1}
============

A urodynamic study (UDS) is a widely used diagnostic tool for the evaluation of female lower urinary tract dysfunction \[[@CR1]\]. Urinary tract infection (UTI) is the most common complication associated with UDS, as the required urethral catheterization may cause tissue damage and the introduction of external pathogens \[[@CR2]\]. Incidence estimates of UTI following UDS vary widely; however, the literature reports rates as high as 28% \[[@CR3]\]. The specific risk factors identified in the literature include older age, elevated BMI, being multiparous, hypothyroidism, diabetes, advanced pelvic organ prolapse, previous surgery for treatment of incontinence and UTI before urodynamic investigation \[[@CR2], [@CR4], [@CR5]\].

Prophylactic measures often taken to prevent UTI after UDS include appropriate patient selection, pre-procedure urine culture screening, antiseptic urethral meatal cleaning and medical prophylaxis with antibiotics. The American College of Obstetricians and Gynecologists (ACOG) June 2018 practice bulletin did not, however, recommend routine antibiotic prophylaxis for women undergoing UDS \[[@CR6]\]. This decision was based on a 2012 Cochrane review that stated the benefit of prophylactic antibiotic use in reducing symptomatic UTI after UDS was still unclear based on "a lack of good quality studies and the need for robustly conducted and sufficiently powered randomized controlled trials" \[[@CR7]\]. Conversely, the Society of Obstetricians and Gynecologists of Canada (SOGC) 2018 reaffirmed practice guideline endorsed antibiotic prophylaxis but only when the incidence of UTI following UDS was found to be \> 10% in the patient population of interest \[[@CR3], [@CR8]\]. Remarkably, this recommendation was based on a study that was authored by one of the guideline authors and was made despite the poorly established variable rates of incidence and limited scientific evidence, particularly in female patients. No societal recommendations exist based on female-specific literature. In fact, no systematic reviews exist on this topic based purely on female data, surprisingly given that many of the risk factors for UTI following UDS and cystoscopy are associated with patients being female.

Anecdotally, we find physicians each weigh the risks of a UTI post UDS against the risks of prophylactic antibiotics (such as increased microbial resistance patterns \[[@CR9]\]), and there is no consensus on when prophylactic antibiotics are warranted. In this study, we aim to update the 2012 Cochrane review and present the first female-specific systematic review with the primary objective of evaluating the efficacy of antibiotic prophylaxis compared with placebo or no treatment for prevention of UTI in females over the age of 18 years undergoing UDS.

Methods {#Sec2}
=======

The conduct and reporting of this review adhere to the principles outlined by the Centre of Reviews and Dissemination as well as the PRISMA guidelines \[[@CR10]--[@CR12]\] and is registered in PROSPERO-international prospective register of systematic reviews (ID\#: CRD42020158347).

Eligibility criteria {#Sec3}
--------------------

### Studies {#FPar1}

As the prior 2012 Cochrane systematic review on this topic included studies published up to and including 2009, for this current review, randomized controlled trials and quasi-randomized controlled trials published from January 2009 to June 2019 were included. No language restrictions were applied.

### Participants {#FPar2}

Females 18 years of age or older who underwent UDS.

### Interventions {#FPar3}

Planned intervention of antibiotic prophylaxis.

### Comparison {#FPar4}

Planned comparator of placebo, no intervention or any other intervention.

### Outcomes {#FPar5}

The primary outcome was the incidence of UTI in the intervention and comparator groups, as defined by each study.

Search strategy {#Sec4}
---------------

After several scoping searches, the keywords of relevant records and all NIH MeSH terms were reviewed by two study investigators. The full search strategy was then developed in conjunction with the research librarian associated with the study, and the systematic search was performed in MEDLINE, CINAHL, EMBASE, ProQuest Dissertations & Theses Global and COCHRANE on June 20, 2019. A sample search strategy for MEDLINE is shown in the Appendix Table [3](#Tab3){ref-type="table"}. Any results from the electronic search that were proceedings of entire conferences were kept separately and hand searched. As well, reference lists of included studies, relevant systematic reviews and clinical trial registries were reviewed. Corresponding authors of included papers were contacted by email for information regarding studies in progress and unpublished research. Finally, searches were repeated November 7, 2019, and May 5, 2020, to identify any relevant new publications.

Screening and selection {#Sec5}
-----------------------

Using Covidence™ systematic review software (Veritas Health Innovation, Melbourne, Australia), two study investigators independently screened all unique titles and abstracts and then resolved any discrepancies via consensus. Full-text articles were obtained for all abstracts included. The same two investigators then assessed the relevance of each full-text article independently, according to eligibility criteria. Authors were contacted by email for female-specific data if their studies presented both male and female data but otherwise met the inclusion criteria. Any discrepancies were resolved by consensus or in conjunction with a third study investigator as required.

Data extraction and quality assessment {#Sec6}
--------------------------------------

A standardized data extraction tool was first piloted and modified and then applied by two independent study investigators. Categories of data collected included study characteristics, design, methods including inclusion and exclusion criteria and UTI definition and identification, participant demographics, interventions, outcomes and adverse events. The trials were critically appraised using the modified Cochrane Collaboration tool to assess risk of bias of randomized controlled trials \[[@CR13]\]. The modified Cochrane Collaboration tool was also used to report on funding bias while maintaining prior established validity. Any discrepancies were resolved in discussion with a third study investigator.

Methods of synthesis and analysis {#Sec7}
---------------------------------

Statistical analysis was performed according to Cochrane Collaboration guidelines in R-studio (RStudio Inc., Boston, MA). Data from intention-to-treat analysis were used where available. Results were given as odds ratios with 95% confidence interval and reported in forest plots. The primary outcome was symptomatic UTI following UDS in female patients treated with antibiotic prophylaxis compared with placebo or no treatment. Secondary outcomes included asymptomatic bacteriuria and adverse events in the same population studied.

Meta-analysis was not performed as the assumption of homogeneity was not met. Key clinical heterogeneity was noted in the intervention, i.e., the choice of antibiotic, its dosing and timing as well as outcome (i.e., UTI definition) (Appendix Table [4](#Tab4){ref-type="table"}). The statistical heterogeneity between trials was also assessed by forest plot analysis. Subgroup analysis and publication bias/selective reporting analysis were not performed given the limited number of included studies.

Other quantitative descriptive data collected were summarized in fractions and ranges. Patient characteristics depicted by means and standard deviations in their studies of origin were assumed to be normally distributed and presented as median and intraquartile ranges for better comparison between studies. Student's t-tests were also applied to normal characteristic data comparing the intervention and comparator groups where appropriate and not previously published.

Results {#Sec8}
=======

Description of studies {#Sec9}
----------------------

A total of 2811 records were screened for this review. The flow of literature through the search and appraisal process is shown in the PRISMA diagram (Fig. [1](#Fig1){ref-type="fig"}). Five randomized controlled trials comparing the effectiveness of antibiotic prophylaxis in female patients were identified as relevant. Two trials were excluded from the review, one because the author did not respond to the request for female-specific data and the other because the author replied to the request for female-specific data, but data provided were incongruent with published results. Three randomized controlled trials involving 325 patients in total were included in this review \[[@CR14]--[@CR16]\]. An overview of these studies can be found in Table [1](#Tab1){ref-type="table"}. Demographic characteristics and patient exclusion criteria by study are given in Table [2](#Tab2){ref-type="table"}. Detailed characteristics of included and excluded studies can be found in Appendices Table [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}.Fig. 1PRISMA diagram: Flow of literature through the search and appraisal processTable 1Characteristics of included studiesSourceSettingN^a^Interventionn^a^Comparatorn^a^OutcomeFollow-upHirakauva 2017 \[[@CR14]\]Brazil217Levofloxacin 500 mg59Placebo63Bacteriuria, UTI^b^ symptoms, adverse events14 days after UDS^b^Trimethoprim-sulfamethoxazole 80 mg/400 mg48Nitrofurantoin 100 mg47Palleschi 2017 \[[@CR15]\]Italy36Prulifloxacin 400 mg17D-mannose 500 mg, N-acetylcysteine 100 mg, *Morinda citrifolia* fruit extract 300 mg19Bacteriuria, UTI^b^ symptoms, adverse events10 days after UDS^b^Miotla 2018 \[[@CR16]\]Poland72Fosfomycin trometamol 1 dose35Phytodrug containing centaury herb, lovage root, and rosemary leaves37Bacteriuria, UTI^b^ symptoms, adverse events7 days after UDS^ba^N represents total number of patients, n represents number of patients in each group^b^Abbreviations: UTI, urinary tract infection; UDS, urodynamic studiesTable 2A. Demographic characteristics by study. B. Exclusion characteristics by studyASourceMedian age (IQR^a^)Median BMI^a^ (IQR^a^)Mean parity (SD^a^)Menopause (%)ABX^a^ControlABX^a^ControlABX^a^ControlABX^a^ControlHirakauva 2017 \[[@CR14]\]Levofloxacin49 (42--56)51 (45--57)26 (24--28)26 (24--28)3.34 (1.70)3.19 (1.64)42.4%52.4%TMP/SMX^a^49 (42--56)26 (24--27)3.15 (1.09)50.0%Nitrofurantoin45 (38--52)26 (23--29)2.87 (1.15)36.2%Palleschi 2017 \[[@CR15]\]Purlifloxacin56 (48--64)54 (43--66)*p* \> 0.0570.6%57.9%Miotla 2018 \[[@CR16]\]Fosfomycin63 (55--70)64 (57--71)30 (28--33)30 (28--33)2.1 (1.12)2.3 (0.97)80%83.7%BExclusion criteriaSourceHirakauva 2017^14^Palleschi 2017^15^Miotla 2018^16^Positive urine culture, urinalysis or UTI^a^ symptoms pre-UDS^a^xxxAllergy to study antibioticsxPregnancyxIntermittent self-catheterizationxLong-term catheterization (indwelling/permanent catheter or nephrostomy/suprapubic catheter/ureteral stent or long-term catheter in last 3 month)xxRecent urogynecological surgeryxGenital prolapse exceeding genital hiatusxEvidence of interstitial cystitisxHistory of hematuriaxCurrent or recent antibiotic usexDiabetes mellitusxNeoplastic disease/evidence of suspicious fistulax^a^Abbreviations: IQR, interquartile range; BMI, body mass index; SD, standard deviation; ABX, antibiotics; TMP/SMX, trimethoprim-sulfamethoxazole; UTI, urinary tract infection; UDS, urodynamics studies

Risk of bias and effects of intervention in included studies {#Sec10}
------------------------------------------------------------

One study was appraised to have an overall low risk for bias, while the other two were identified as high risk for bias in at least three domains evaluated (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). The cumulative odds of women developing a UTI after UDS was higher in those that did not receive antibiotic prophylaxis than in those that did. However, analysis of individual study results through a forest plot demonstrated no significant trend (Fig. [4](#Fig4){ref-type="fig"}i). The cumulative odds of women developing bacteriuria after UDS were also higher in those that did not receive antibiotics prophylaxis than in those that did. In this scenario, analysis of individual study results in a forest plot demonstrated a trend towards a protective effect of antibiotic prophylaxis against bacteriuria following UDS (Fig. [4](#Fig4){ref-type="fig"}ii and iii). All three studies intended to report on adverse events but no adverse events were reported in any participant.Fig. 2Risk of bias: authors' judgments about each risk of bias item for each studyFig. 3Risk of bias: authors' judgments about each risk of bias item as percentages across all three included studiesFig. 4Forest plot for antibiotics versus any other intervention: i. Outcome UTI, by study. ii. Outcome bacteriuria, by study. iii. Outcome bacteriuria, for specific antibiotics

Discussion {#Sec11}
==========

As in the prior 2012 Cochrane review on this subject, our review of three randomized controlled trials did indicate that prophylactic antibiotics may reduce the risk of bacteriuria after UDS; however, there is not enough evidence to suggest this same intervention reduces the risk of UTI after UDS \[[@CR7]\]. The study critically appraised as least likely biased showed a statistically significant effect of antibiotic prophylaxis in reducing bacteriuria following UDS \[[@CR14]\], but it was not powered to show a significant change in incidence of UTI after UDS and thus it did not demonstrate an effect of antibiotic prophylaxis on UTI incidence after UDS in female patients \[[@CR14]\]. The other two reviewed studies showed neither an effect of antibiotic prophylaxis on bacteriuria or UTI incidence in women undergoing UDS \[[@CR15], [@CR16]\].

The range of incidences of UTI post UDS in the reviewed studies (0.5%, 2.8% and 5.6%) was only comparable to the lower end of the spectrum of the published incidence rates of 4.3% to 19% \[[@CR2], [@CR4], [@CR5]\]. Additionally, the rate of bacteriuria in the reviewed studies (2.8%, 4.1%, and 5.6%) was notably low when compared to published incidence rates of 7.9% to 11.6% \[[@CR4], [@CR17]\]. This female-specific systematic review therefore supports the SOGC guideline in not recommending antibiotic prophylaxis based on its chosen decision rule \[[@CR3], [@CR8]\].

Of the randomized control studies included, only one was found to have a low risk of bias \[[@CR14]\]. The other two studies may have been influenced by a possible conflict of interest as well as performance bias and attrition bias \[[@CR15], [@CR16]\]. This, in combination with the above noted low incidence of outcomes in these small sample-size studies, means the present review demonstrates a continued need for further research and that the current ACOG guideline recommendation to not use antibiotics based on a lack of evidence is appropriate \[[@CR6], [@CR7], [@CR18]\].

Our study boasts a robust search strategy created in collaboration with a research librarian. This review was primarily limited by the lack of good quality evidence and this is the cause of our inability to further define the efficacy of antibiotic prophylaxis for UDS. Like our predecessors, our results must be interpreted with caution. The standard Cochrane risk-bias tool defined study biases and publication bias aside, further specific caveats to this review include the high degree of heterogeneity in antibiotic dose, duration and timing, timing of pre- and post-urodynamic urine culture and the heterogeneity in reporting of symptoms in women with bacteriuria after UDS. Furthermore, the definition of a UTI, transient bacteremia or asymptomatic bacteriuria in this patient population is very difficult. Thus, the definition alone of incidence in this population may be controversial, this even before considering self-reporting bias, validity and reliability.

The results of this review mean we must advocate for more research in this area, particularly female-specific research, such that practitioners performing UDS can make an informed decision with regard to the benefits of antibiotic prophylaxis versus the possible negative effects including increased antibiotic resistance and decreased microbiome diversity \[[@CR9], [@CR19], [@CR20]\]. Of course, other considerations to decrease the risk of infection associated with catheterization are already being explored in the form of protein, silver and nitrazine coating of catheters, surface micropatterns on catheters and variable pre-procedural meatal cleaning \[[@CR21]--[@CR26]\]. In addition, alternative UTI prophylaxis with cranberry juice, cranberry extract, N-acetylcysteine and lactobacilli is also an emerging field of research to consider in this ongoing debate \[[@CR15], [@CR16], [@CR27]--[@CR33]\].

Conclusion {#Sec12}
==========

This systematic review of the literature demonstrates that antibiotic prophylaxis may significantly decrease bacteriuria in women following UDS; however, studies included in this review were not powered effectively to address the effect of antibiotic prophylaxis on UTI incidence in women after UDS. Further research is required to assess statistical and clinical efficacy of antibiotic prophylaxis against UTI after UDS in female patients.

Appendix {#Sec13}
========

Table 3Medline search strategy1 Antibiotic Prophylaxis/ (13107)2 PREMEDICATION/ (12385)3 POST-EXPOSURE PROPHYLAXIS/ (1064)4 Pre-Exposure Prophylaxis/ (1465)5 premedication\*.ti,ab. (8065)6 post exposure prophyla\*.ti,ab. (1691)7 (antibiotic\* adj2 prophyla\*).tw,kf. (14603)8 (antibiotic\* adj2 premedication\*).tw,kf. (19)9 pre exposure prophyla\*.tw,kf. (2190)10 preexposure prophyla\*.tw,kf. (736)11 post exposure prevent\*.tw,kf. (33)12 Urinary Tract Infections/ (37484)13 urinary tract infection\*.tw,kf. (39800)14 UTI.tw. (8600)15 urinary infection\*.tw,kf. (4945)16 bladder infection\*.tw,kf. (324)17 BACTERIURIA/ (7526)18 bacteriuria\*.tw,kf. (5868)19 Urodynamics/ (14788)20 urodynamic\*.tw,kf. (11899)21 (urodynamic\* adj2 study).tw. (1330)22 (urodynamic\* adj2 studies).tw. (1932)23 UDS.tw. (1485)24 uroflow\*.tw,kf. (2775)25 Urinary Bladder/ (49012)26 (bladder adj2 function\*).tw,kf. (4402)27 CYSTOSCOPY/ (7338)28 cystoscopy.tw,kf. (7350)29 cystoscop\*.tw,kf. (9742)30 (cystoscop\* adj2 surg\*).tw,kf. (116)31 (cystoscop\* adj2 procedur\*).tw,kf. (140)32 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (45705)33 (urine adj2 infect\*).tw,kf. (1048)34 (urinary adj2 infect\*).tw,kf. (44323)35 12 or 13 or 14 or 15 or 16 or 17 or 18 or 33 or 34 (64883)36 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 (78376)37 Early Medical Intervention/ (2586)38 early medical interven\*.tw,kf. (190)39 Primary Prevention/ (17547)40 primary prevent\*.tw,kf. (18589)41 Secondary Prevention/ (19113)42 secondary prevent\*.tw,kf. (18134)43 Anti-Infective Agents/ (50937)44 antiinfective agent\*.tw,kf. (97)45 anti infective agent\*.tw,kf. (1440)46 anti microbial agent\*.tw,kf. (362)47 antibiotic\*.ti,ab. (310858)48 antibiotic\*.tw,kf. (324004)49 Nitrofurantoin/ (2595)50 nitrofurantoin.ti,ab,tw,kf. (3480)51 Fosfomycin/ (1896)52 fosfomycin.ti,ab,tw,kf. (2748)53 beta-Lactams/ (6289)54 beta lactams.ti,ab,tw,kf. (7677)55 Trimethoprim, Sulfamethoxazole Drug Combination/ or Trimethoprim/ (11691)56 trimethoprim.ti,ab,tw,kf. (15991)57 Fluoroquinolones/ (12992)58 fluroquinolones.ti,ab,tw,kf. (67)59 Urological Agents/ (654)60 urolog\* agent\*.ti,ab,tw,kf. (6)61 N-acetylcysteine D-mannose.ti,ab,tw,kf. (2)62 NAC.ti,ab,tw,kf. (17583)63 32 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 (501083)64 Cystitis/ (7360)65 cystitis.ti,ab,tw,kf. (11160)66 (bladder adj2 infect\*).ti,ab,tw,kf. (798)67 Female Urogenital Diseases/ (2011)68 female urogenital disease\*.ti,ab,tw,kf. (16)69 Reproductive Tract Infections/ (463)70 (reproductive adj2 tract adj2 infect\*).ti,ab,tw,kf. (2770)71 (genital adj2 tract adj2 infect\*).ti,ab,tw,kf. (1442)72 Catheter-Related Infections/ (4468)73 (catheter\* adj2 infect\*).ti,ab,tw,kf. (4601)74 Bacteremia/ (23528)75 bacteremia\*.ti,ab,tw,kf. (23277)76 Gram-Positive Bacterial Infections/ (10459)77 bacteria\* infect\*.ti,ab,tw,kf. (39042)78 Gram-Negative Bacterial Infections/ (11888)79 Bacterial Infections/ (68467)80 Sepsis/ (56098)81 sepsis.ti,ab,tw,kf. (91076)82 Disease Transmission, Infectious/ (8539)83 Cross Infection/ (54468)84 Focal Infection/ (2118)85 Opportunistic Infections/ (11731)86 Prosthesis-Related Infections/ (11416)87 cross infect\*.ti,ab,tw,kf. (3261)88 focal infect\*.ti,ab,tw,kf. (2207)89 opportunistic infect\*.ti,ab,tw,kf. (14238)90 (prosthesis adj2 infect\*).ti,ab,tw,kf. (1159)91 Suppuration/ (7920)92 supperation.ti,ab,tw,kf. (1)93 Biofilms/ (29369)94 biofilm\*.ti,ab,tw,kf. (43540)95 35 or 64 or 65 or 66 or 67 or 68 or 69 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 (453273)96 Diagnostic Techniques, Urological/ (838)97 (diagnos\* adj2 urolog\*).ti,ab,tw,kf. (809)98 Urinary Catheterization/ (13829)99 (urin\* adj2 catheter\*).ti,ab,tw,kf. (6193)100 36 or 96 or 97 or 98 or 99 (93261)101 63 and 95 and 100 (2222)102 limit 101 to humans (1927)

Table 4Detailed characteristics of included studiesHirakauva 2017MethodsPre-test: completed but time not specifiedABX given: 30 min before UDSUDS technique: sterilePost-UDS: culture 14 days after UDSParticipantsPatients undergoing UDS for lower urinary tract symptoms with no bacteriuriaIntervention59 patients received one dose of levofloxacin 500 mg48 patients received one dose of trimethoprim-sulfamethoxazole 80 mg/400 mg47 patients received one dose of nitrofurantoin 100 mg63 patients received one dose of placeboOutcomesBacteriuria (\> 10^5^ CFU/ml): 1 patient from the levofloxacin group, 1 patient from the trimethoprim-sulfamethoxazole group, 1 patient from the nitrofurantoin group and 6 patients from the placebo groupSymptomatic UTI (such as dysuria and pelvic pain): 1 patient from the placebo groupAdverse events: noneNotesNo significant difference in age, parity, BMI and menopause (*p* \> 0.05)Risk of biasBiasAuthors' judgmentSupport for judgmentRandom sequence generation (selection bias)LowAllocation concealment (selection bias)LowNo information given; however, baseline demographic data were similar between comparator groupsBlinding of participants and personnel (performance bias)All outcomesLowDouble-blinded studyBlinding of outcome assessment (detection bias)All outcomesLowIncomplete outcome data (attrition bias)All outcomesLowThere appears to be no loss to follow-upSelective reporting (reporting bias)LowAdverse reactions and UTI rate reportedOther biasLowPalleschi 2017MethodsPre-test: 7 days before UDSABX given: 1st dose starting 1 day before UDSUDS technique: not specifiedPost-UDS: culture 10 days after UDSParticipantsPatients undergoing UDS with no bacteriuriaIntervention17 patients received 5 days of prulifloxacin 400 mg19 patients received 7 days of D-mannose 500 mg, N-acetylcysteine 100 mg, Morinda citrifolia fruit extract 300 mgOutcomesBacteriuria (\> 10^5^ CFU/ml): 1 patient from the prulifloxacin group and 1 patient from the D-mannose, N-acetylcysteine, and Morinda citrifolia fruit extract groupSymptomatic UTI: 1 patient from each groupAdverse events: noneNotesRisk of biasBiasAuthors' judgmentSupport for judgmentRandom sequence generation (selection bias)UnclearAllocation concealment (selection bias)LowNot described; however, comparators appear similarBlinding of participants and personnel (performance bias)All outcomesHighBlinding of outcome assessment (detection bias)All outcomesLowIncomplete outcome data (attrition bias)All outcomesHighSelective reporting (reporting bias)LowOther biasHigh (conflict of Interest)Miotla 2018MethodsPre-test: completed but time not specifiedABX given: after UDSUDS technique: sterilePost-UDS: culture, dipstick and symptom assessment 7 days after UDSParticipantsFemale patients undergoing UDS with no bacteriuria for mixed urinary incontinence, neurogenic bladder or unclear lower urinary tract symptomsIntervention35 patients received one dose of fosfomycin trometamol37 patients received 1 week of phytodrug containing centaury herb, lovage root and rosemary leaves (5 ml taken orally three times daily)OutcomesBacteriuria (\> 10^3^ CFU/ml): 1 patient from the fosfomycin trometamol group and 1 patient from the phytodrug groupSymptomatic UTI: 1 patient from each groupAdverse events: noneNotesNo significant difference between groups in terms of age, BMI, parity and menopauseRisk of biasBiasAuthors' judgmentSupport for judgmentRandom sequence generation (selection bias)LowAllocation concealment (selection bias)LowNot described specifically but unlikely to be a concern as baseline characteristics were similar between comparatorsBlinding of participants and personnel (performance bias)All outcomesHighBlinding of outcome assessment (detection bias)All outcomesLowIncomplete outcome data (attrition bias)All outcomesHigh2 patients were lost to follow-up in the fosfomycin group, which is similar to the total incidence of bacteruriaSelective reporting (reporting bias)LowOther biasHigh (conflict of Interest)

Table 5Detailed characteristics of excluded studiesGurbuz 2013MethodsPre-test: 72 h before UDSABX given: 1 h or 12 h before UDSUDS technique: sterilePost-UDS: culture and symptoms 5--7 days after UDSParticipantsMale and female patients undergoing UDS for urinary incontinence and lower urinary tract symptomsIntervention141 patients received one dose of ciprofloxacin 500 mg137 patients received one dose of fosfomycin tromethamine133 patients received no prophylaxisOutcomesBacteriuria: 6 patients from the ciprofloxacin group, 3 patients from the fosfomycin tromethamine group and 3 patients from the no prophylaxis groupReason for exclusionAuthor replied to the request for female-specific data, but data provided were incongruent with published resultsRahardjo 2016MethodsPre-test: completed but time not specifiedABX given: after UDS completionUDS technique: sterilePost-UDS: urinalysis, culture and symptoms 4 days after UDSParticipantsMale and female patients undergoing UDSIntervention63 patients received 3 days of levofloxacin 500 mg daily63 patients received 3 days of placebo dailyOutcomesBacteriuria: 8 patients from the levofloxacin group, and 18 patients from the placebo groupSymptomatic UTI: 8 patients from the levofloxacin group and 18 patients from the placebo groupReason for exclusionAuthor did not respond to request for female-specific data
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